Contraindications and people who should use sparsentan with caution

Sparsentan is a treatment drug forIgA nephropathy, developed by Travere Therapeutics. It is the first single-molecule dual endothelin (ET-1)-angiotensin II type 1 (AT1R) receptor antagonist (DEARA) designed to selectively block two pathways associated with the progression of IgA nephropathy. The drug received accelerated approval from the US FDA in February 2023 and is used to reduce proteinuria in adult patients with primary IgA nephropathy who are at risk of rapid disease progression. It has the effect of significantly reducing proteinuria, but it is not suitable for everyone. Before using it, it is important to understand the contraindications of sparsentin and who should use it with caution.

1. Contraindications

1. Allergy Disabled: Do not use if you are allergic to any ingredients in Sparsentan.

2. Contraindicated for pregnant women: Sparsentan is contraindicated for pregnant women. Because the drug may cause serious adverse effects on the fetus. For patients who may be pregnant, they must confirm that they are not pregnant before starting to take sparsentan, and take effective contraceptive measures during treatment and within 1 month after stopping the drug to avoid pregnancy. At the same time, these patients also need to take monthly pregnancy tests to ensure that the results are negative. If you have already had your fallopian tubes sterilized, or have an intrauterine device (IUD) or progesterone implant, these methods can be used alone without the need for other forms of birth control. Before changing contraceptive methods, please be sure to communicate with your attending doctor to ensure that you choose another effective contraceptive method.

3. Drug interactions: Do not take sparsentan simultaneously with angiotensin receptor blockers (ARBs), ERAs, or aliskiren, as this may increase the risk of adverse drug reactions.

2. Use with caution

1. Patients with hepatic impairment: Because endothelin receptor antagonists (ERAs) are associated with elevated transaminases, hepatotoxicity, and cases of liver failure, sparsentan should be used with caution in patients with hepatic impairment. Liver function should be assessed before treatment is initiated and monitored closely during treatment.

2. Patients with cardiac impairment: Sparsentane should be used with caution in patients with underlying left ventricular dysfunction or underlying heart failure as the drug may increase the risk of severe fluid retention.

3. Patients with renal impairment: Sparsentane is associated with a risk of renal impairment, including acute kidney injury and hyperkalemia. Therefore, use with caution and close monitoring of renal function in patients with renal artery stenosis, chronic kidney disease, severe congestive heart failure, or volume failure.

4. Patients taking other medications: Tell your doctor about all the medications you are currently taking. Sometimes it may not be safe to use certain drugs together because some drugs, such as antacids, can affect your blood levels of other drugs you are taking, increasing side effects or making the drugs less effective.

In short, before using sparsentan, be sure to consult a doctor and inform your personal health status and medication history to ensure safe use. Sparsentin is currently sold overseas. Prices vary depending on the version. Please choose by yourself.